Cancer type | CAF subtype | Biological effect | Refs. |
---|---|---|---|
ER+ breast cancer | CD146pos CAFs | Maintain ER expression and sustain sensitivity to tamoxifen | Brechbuhl et al. (2017) |
Pancreatic cancer | α-SMA+ CAFs | Mediate T-effector cell to Treg ratio and promote immune infiltration | McAndrews et al. (2022) |
Breast Cancer | Asporin+ CAFs | Inhibition of TGF-β1-mediated SMAD2 phosphorylation, EMT process and stemness | Maris et al. (2015) |
Fibrosarcoma | VCAN+ CAFs | Remodel the ECM and maintain the tumor-inhibitory functions | Fanhchaksai et al. (2016) |
Lung cancer | low-HGF/low-FGF7 CAFs | Exert chemoattraction for immune cell infiltration and reverse ICB resistance | |
Pancreatic cancer | Meflin+ CAFs | Suppress the progression of tumor | Mizutani et al. (2019) |
Pancreatic cancer | α-SMA+ CAFs | Inhibit accumulation of CD4 + FOXP3 + Tregs and immunosuppressive microenvironment formation | Ozdemir et al. (2014) |